新聞中心及演示文稿
上一篇文章   |   下一篇文章
監管信息公告, 監管通知 | 2015-04-08

Directors’ Shareholding

London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the “Shares”) as follows:-

Director

Date of
purchase

Number of Shares
purchased

Purchase price

Beneficial interest in Shares following purchases

Number
of Shares

% of total issued
share capital

Simon To
(Executive Director and Chairman)

2 April 2015

7 April 2015

10,000

48,000

GBP13.85

GBP13.85

127,000

0.24%

Edith Shih
(Non-executive Director and Company Secretary)

2 April 2015

7 April 2015

10,000

2,000

GBP13.85

GBP13.85

60,000

0.11%

Ends

Enquiries

Chi-Med
Telephone: +852 2121 8200
Christian Hogg, CEO

Panmure Gordon (UK) Limited
Telephone: +44 20 7886 2500
Richard Gray
Andrew Potts

Citigate Dewe Rogerson
Telephone: +44 20 7638 9571
Anthony Carlisle Mobile: +44 7973 611 888
David Dible Mobile: +44 7967 566 919

About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.